In oncology, HLA Class I genotypes and diversity have been linked not only to susceptibility to certain cancers but also to the efficacy and immune‐related adverse events of immune‐checkpoint inhibitor therapies, suggesting that HLA‐A‐driven antigen presentation can influence both antitumor immunity and autoimmunity [51, 52, 53]. Here, HLA-A is linked to Autoimmunity.